JPMorgan Chase & Co. grew its stake in shares of Cellectis SA (NASDAQ:CLLS) by 120.3% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 65,145 shares of the biotechnology company’s stock after acquiring an additional 35,580 shares during the period. JPMorgan Chase & Co. owned about 0.16% of Cellectis worth $2,053,000 at the end of the most recent quarter.
Other hedge funds also recently made changes to their positions in the company. Aperio Group LLC acquired a new position in Cellectis during the 1st quarter worth $215,000. Trellus Management Company LLC acquired a new position in Cellectis during the 1st quarter worth $315,000. HBK Investments L P acquired a new position in Cellectis during the 4th quarter worth $498,000. Wells Fargo & Company MN grew its holdings in Cellectis by 101.8% during the 1st quarter. Wells Fargo & Company MN now owns 27,483 shares of the biotechnology company’s stock worth $866,000 after acquiring an additional 13,866 shares in the last quarter. Finally, Bellevue Group AG grew its holdings in Cellectis by 114.0% during the 1st quarter. Bellevue Group AG now owns 52,100 shares of the biotechnology company’s stock worth $1,642,000 after acquiring an additional 27,750 shares in the last quarter. 16.76% of the stock is owned by institutional investors.
Cellectis stock opened at $28.39 on Thursday. Cellectis SA has a 1 year low of $21.25 and a 1 year high of $38.85.
Cellectis (NASDAQ:CLLS) last posted its quarterly earnings results on Monday, May 7th. The biotechnology company reported ($0.71) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.70) by ($0.01). Cellectis had a negative return on equity of 37.45% and a negative net margin of 337.45%. The business had revenue of $8.07 million during the quarter, compared to the consensus estimate of $9.53 million. research analysts forecast that Cellectis SA will post -2.59 EPS for the current year.
CLLS has been the subject of several recent analyst reports. Nomura raised their price objective on shares of Cellectis to $73.00 and gave the stock a “buy” rating in a report on Wednesday, March 14th. ValuEngine raised shares of Cellectis from a “hold” rating to a “buy” rating in a report on Monday, April 2nd. Guggenheim initiated coverage on shares of Cellectis in a report on Friday, March 16th. They set a “neutral” rating for the company. BidaskClub lowered shares of Cellectis from a “buy” rating to a “hold” rating in a report on Wednesday, March 21st. Finally, Zacks Investment Research raised shares of Cellectis from a “hold” rating to a “buy” rating and set a $32.00 price objective for the company in a report on Tuesday, May 15th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and four have assigned a buy rating to the stock. The stock has an average rating of “Hold” and an average price target of $42.67.
Cellectis SA, a clinical stage biotechnological company, develops and sells immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer in France. The company operates through two segments, Therapeutics and Plants. Its lead product candidate is UCART19, an allogeneic T-cell product candidate for the treatment of CD19 expressing hematologic malignancies, which develop in acute lymphoblastic leukemia (ALL).
Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.